Constitutively Overexpressed Erythropoietin Reduces Infarct Size in a Mouse Model of Permanent Coronary Artery Ligation

Methods in Enzymology

Volumn 435, Issue , 2007, Pages

  Camici, Giovanni G ^a   Stallmach, Thomas ^a,b   Hermann, Matthias ^a   Hassink, Rutger ^c   Doevendans, Peter ^c   Grenacher, Beat ^a   Hirschy, Alain ^d   Vogel, Johannes ^a   Lüscher, Thomas F ^a   Ruschitzka, Frank ^a   Gassmann, Max ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Department of Cardio Thoracic Surgery   (Netherlands)

^d ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EOSIN; ERYTHROPOIETIN; HEMATOXYLIN; RECOMBINANT ERYTHROPOIETIN; WT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COMPUTER ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORRELATION FUNCTION; DISEASE MARKER; GENE EXPRESSION; GENE OVEREXPRESSION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MORPHOMETRICS; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRAIN DIFFERENCE; SUPPRESSOR GENE; TRANSGENIC MOUSE; TREATMENT OUTCOME; WILD TYPE; ANIMAL; ARTICLE; BLOOD; CORONARY BLOOD VESSEL; DISEASE MODEL; GENETICS; HEART INFARCTION; HUMAN; METABOLISM; PATHOLOGY;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

ANIMALS; BIOLOGICAL MARKERS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATOCRIT; HUMANS; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; WT1 PROTEINS;

EID: 39749165724     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)35008-8     Document Type: Review

References (19)

1. Bogdanova A., Mihov S., Lutz H., Saam B., Gassmann M., and Vogel J. Enhanced erythro-phagocytosis in polycytemic mice overexpressing erythropoietin. Blood 110 (2007) 762-769
2. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signaling cascades. Nature 412 (2001) 641-647
3. Fandrey J., Gorr T.A., and Gassman M. Regulating cellular oxygen sensing by hydroxylation. Cardiovascular Res. 71 (2006) 642-651
4. Jewell U.R., Kvietikova I., Scheid A., Bauer C., Wenger R.H., and Gassmann M. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J. 15 (2001) 1312-1314
5. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
6. Moon C., Krawczyk M., Ahn D., Ahmet I., Paik D., Lakatta E.G., and Talan M.I. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. USA 100 (2003) 11612-11617
7. Namiuchi S., Kagaya Y., Ohta J., Shiba N., Sugi M., Oikawa M., Kunii H., Yamao H., Komatsu N., Yui M., Tada H., Sakuma M., et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 45 (2005) 1406-1412
8. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., Thompson R.B., Petrofski J.A., Annex B.H., Stamler J.S., and Koch W.J. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112 (2003) 999-1007
9. Ruschitzka F.T., Wenger R.H., Stallmach T., Quaschning T., de Wit C., Wagner K., Labugger R., Kelm M., Noll G., Rulicke T., Shaw S., Lindberg R.L., et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 97 (2000) 11609-11613
10. Schofield C.J., and Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5 (2004) 343-354
11. Scholz H., and Kirschner K.M. A role for the Wilms' tumor protein WT1 in organ development. Physiology (Bethesda) 20 (2005) 54-59
12. Vargas S.O., Sampson B.A., and Schoen F.J. Pathologic detection of early myocardial infarction: A critical review of the evolution and usefulness of modern techniques. Mod. Pathol. 12 (1999) 635-645
13. Vesey D.A., Cheung C., Pat B., Endre Z., Gobe G., and Johnson D.W. Erythropoietin protects against ischaemic acute renal injury. Nephrol. Dial. Transplant 19 (2004) 348-355
14. Vogel J., Kiessling I., Heinicke K., Stallmach T., Ossent P., Vogel O., Aulmann M., Frietsch T., Schmid-Schonbein H., Kuschinsky W., and Gassmann M. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity. Blood 102 (2003) 2278-2284
15. Wagner K.D., Wagner N., Bondke A., Nafz B., Flemming B., Theres H., and Scholz H. The Wilms' tumor suppressor WT1 is expressed in the coronary vasculature after myocardial infarction. FASEB J. 16 (2002) 1117-1119
16. Wagner K.D., Wagner N., Wellmann S., Schley G., Bondke A., Theres H., and Scholz H. Oxygen-regulated expression of the Wilms' tumor suppressor WT1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J. 17 (2003) 1364-1366
17. Wagner K.F., Katschinski D.M., Hasegawa J., Schumacher D., Meller B., Gembruch U., Schramm U., Jelkmann W., Gassmann M., and Fandrey J. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97 (2001) 536-542
18. Wiessner C., Allegrini P.R., Ekatodramis D., Jewell U.R., Stallmach T., and Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J. Cereb. Blood Flow Metab. 21 (2001) 857-864
19. Yang C.W., Li C., Jung J.Y., Shin S.J., Choi B.S., Lim S.W., Sun B.K., Kim Y.S., Kim J., Chang Y.S., and Bang B.K. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 17 (2003) 1754-1755